Aegerion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AEGR)

$1.97 0.10 (5.35 %)
(As of 12/13/2017 04:12 AM ET)
Previous Close$1.87
Today's Range$1.86 - $2.34
52-Week Range$1.23 - $10.85
Volume2.17 million shs
Average Volume635,262 shs
Market Capitalization$56.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5

About Aegerion Pharmaceuticals (NASDAQ:AEGR)

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Receive AEGR News and Ratings via Email

Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:AEGR
CUSIP00767E10
Phone+1-617-5007867

Debt

Debt-to-Equity Ratio-19.22%
Current Ratio1.02%
Quick Ratio0.67%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($5.97)
Net IncomeN/A
Net Margins-75.07%
Return on EquityN/A
Return on Assets-29.21%

Miscellaneous

Employees318
Outstanding Shares29,540,000

Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions

What is Aegerion Pharmaceuticals' stock symbol?

Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."

How were Aegerion Pharmaceuticals' earnings last quarter?

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) issued its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing the Zacks' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to analyst estimates of $43 million. The firm's revenue was down 39.9% on a year-over-year basis. During the same period last year, the business earned ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.

Who are some of Aegerion Pharmaceuticals' key competitors?

How do I buy Aegerion Pharmaceuticals stock?

Shares of Aegerion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aegerion Pharmaceuticals' stock price today?

One share of Aegerion Pharmaceuticals stock can currently be purchased for approximately $1.97.

How big of a company is Aegerion Pharmaceuticals?

Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe.

How can I contact Aegerion Pharmaceuticals?

Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.


MarketBeat Community Rating for Aegerion Pharmaceuticals (AEGR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aegerion Pharmaceuticals (NASDAQ:AEGR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.332.332.20
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.50$8.25$8.25$8.88
Price Target Upside: 23.86% downside318.78% upside318.78% upside350.51% upside

Aegerion Pharmaceuticals (NASDAQ:AEGR) Consensus Price Target History

Price Target History for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Aegerion Pharmaceuticals (NASDAQ:AEGR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2016CowenReiterated RatingHold$1.50N/AView Rating Details
11/11/2016J P Morgan Chase & CoInitiated CoverageHoldN/AView Rating Details
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00N/AView Rating Details
2/12/2016Bank of AmericaDowngradeNeutral -> Underperform$6.00N/AView Rating Details
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Aegerion Pharmaceuticals (NASDAQ:AEGR) Earnings History and Estimates Chart

Earnings by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Aegerion Pharmaceuticals (NASDAQ AEGR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details
8/5/2015Q2($0.27)($0.01)$58.98 million$64.20 millionViewN/AView Earnings Details
10/30/2014Q314($0.18)($0.12)$48.60 million$43.70 millionViewN/AView Earnings Details
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details
5/6/2014Q1($0.35)($0.54)$33.58 million$27.00 millionViewListenView Earnings Details
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Aegerion Pharmaceuticals (NASDAQ:AEGR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aegerion Pharmaceuticals (NASDAQ AEGR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Institutional Ownership by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Aegerion Pharmaceuticals (NASDAQ AEGR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy75,000$1.75$131,250.00View SEC Filing  
9/12/2016Healthcare Master Fun BroadfinMajor ShareholderBuy276,000$1.66$458,160.00View SEC Filing  
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aegerion Pharmaceuticals (NASDAQ AEGR) News Headlines

Source:
DateHeadline
Reviewing Abbott Laboratories (ABT) and Aegerion Pharmaceuticals (AEGR)Reviewing Abbott Laboratories (ABT) and Aegerion Pharmaceuticals (AEGR)
www.americanbankingnews.com - November 28 at 11:16 AM
Head-To-Head Comparison: Aegerion Pharmaceuticals (AEGR) and Neos Therapeutics (NEOS)Head-To-Head Comparison: Aegerion Pharmaceuticals (AEGR) and Neos Therapeutics (NEOS)
www.americanbankingnews.com - November 8 at 7:28 PM
Aegerion Pharmaceuticals (AEGR) & Its Rivals Head-To-Head AnalysisAegerion Pharmaceuticals (AEGR) & Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - October 20 at 12:22 PM
Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
finance.yahoo.com - October 5 at 12:21 PM
Aegerions Juxtapid Gets Pricing Authorization in JapanAegerion's Juxtapid Gets Pricing Authorization in Japan
finance.yahoo.com - October 5 at 12:21 PM
Criminal and civil actions filed against Aegerion Pharmaceuticals Inc.Criminal and civil actions filed against Aegerion Pharmaceuticals Inc.
www.prnewswire.com - September 23 at 9:33 AM
Head to Head Review: Novo Nordisk A/S (NVO) vs. Aegerion Pharmaceuticals (NASDAQ:AEGR)Head to Head Review: Novo Nordisk A/S (NVO) vs. Aegerion Pharmaceuticals (NASDAQ:AEGR)
www.americanbankingnews.com - August 15 at 6:32 AM
Tetraphase Pharmaceuticals (TTPH) and Aegerion Pharmaceuticals (NASDAQ:AEGR) Head-To-Head AnalysisTetraphase Pharmaceuticals (TTPH) and Aegerion Pharmaceuticals (NASDAQ:AEGR) Head-To-Head Analysis
www.americanbankingnews.com - July 30 at 12:20 AM
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a MaterAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater
biz.yahoo.com - November 30 at 10:12 AM
Aegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID PricingAegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID Pricing
www.streetinsider.com - November 19 at 8:26 PM
Aegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID Pricing - StreetInsider.comAegerion Pharma (AEGR) Receives Approval in Japan for JUXTAPID Pricing - StreetInsider.com
www.streetinsider.com - November 17 at 8:35 PM
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - November 7 at 9:49 PM
Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3
www.zacks.com - November 4 at 3:16 PM
Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3 - NasdaqAegerion (AEGR) Reports Narrower-than-Expected Loss in Q3 - Nasdaq
www.nasdaq.com - November 4 at 12:52 PM
Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial ... - GlobeNewswire (press release)Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial ... - GlobeNewswire (press release)
globenewswire.com - November 4 at 12:52 PM

SEC Filings

Aegerion Pharmaceuticals (NASDAQ:AEGR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aegerion Pharmaceuticals (NASDAQ:AEGR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aegerion Pharmaceuticals (NASDAQ AEGR) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.